Adamas Pharmaceuticals Issued U.S. Patent Relating to ADS-5102 Program

EMERYVILLE, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the United States Patent and Trademark Office (USPTO) issued US Patent No. 9,072,697 entitled "Composition and Method for Treating Neurologic Disease." The claims of this patent are directed towards methods for the once-daily administration to Parkinson's patients of amantadine HCl formulations having specific dissolution profiles, including methods for osmotic delivery. The claims include products that are formulated as extended-release only or as a combination of both extended-release and immediate-release drugs.

"This patent, which was filed in 2005, represents an important expansion of our intellectual property surrounding ADS-5102 and is intended to cover products that we or others may seek to bring to market," said Gregory T. Went, Ph.D., Chairman and CEO of Adamas Pharmaceuticals, Inc. "We are committed to protecting our discoveries that have led to the ongoing development of extended-release amantadine formulations being evaluated for the treatment of neurological disorders."

About ADS-5102

Adamas' most advanced wholly owned product candidate is ADS-5102 (amantadine HCl), an extended-release version of amantadine that is administered once daily at bedtime. ADS-5102 is designed to achieve higher plasma concentrations in the early morning, sustained throughout the afternoon, and lower concentrations in the evening. Adamas is currently evaluating ADS-5102 in Phase 3 clinical trials for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and in a Phase 2 clinical trial for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. There are currently no approved drugs in the United States or Europe for the treatment of LID.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company achieves this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone or in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes two approved products with Forest Laboratories Holdings Limited (a subsidiary of Allergan plc), Namzaric™ and Namenda XR®. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. For more information, please visit www.adamaspharma.com.

Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.

Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the ongoing protection and expansion of intellectual property surrounding ADS-5102 and amantadine formulations for neurological disorders. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "would," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to the competitive environment and the effectiveness of the intellectual property portfolio, as well as risks relating to Adamas' business in general, see Adamas' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2015. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release.

CONTACT: For questions, please contact: Julie Wood Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. Phone: 510-450-3528

Source:Adamas Pharmaceuticals, Inc.